Related Experiment Video

Updated: May 24, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.6K

Prohibitin2 knockdown decreases glioma malignant phenotypes and radio-resistance by inhibiting mitophagy

Xuefei Xue1,2, Huiling Tan1, Xingning Jiang1

  • 1State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, China.

International Journal of Radiation Biology
|March 3, 2025
PubMed
Abstract

Insights

Prohibitin 2 (PHB2) promotes glioma. Knocking down PHB2 inhibits cancer growth and enhances radiosensitivity by reducing mitophagy via the PARL-PGAM5-PINK1-Parkin pathway, offering a new therapeutic target.

Area of Science:

  • Mitochondrial biology
  • Cancer research
  • Neuro-oncology

Background:

  • Prohibitin 2 (PHB2) is implicated in cancer progression and mitophagy.
  • Its role in glioma, a primary brain tumor, is not well understood.
  • Understanding PHB2's function is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of PHB2 in glioma cell phenotype, radiosensitivity, and mitophagy.
  • To explore the underlying molecular mechanisms connecting PHB2 to these processes.
  • To assess PHB2 as a potential therapeutic target for glioma.

Main Methods:

  • PHB2 expression analysis using Western blot, qRT-PCR, and TCGA data.
  • In vitro assessment of glioma cell proliferation, cell cycle, migration, and invasion.
  • Colony formation assays for radiosensitivity evaluation.
  • Co-immunoprecipitation assays to elucidate the PHB2-mitophagy interaction pathway.

Main Results:

  • PHB2 expression is upregulated in glioma and correlates with malignancy.
  • PHB2 knockdown suppresses glioma cell proliferation, migration, and invasion.
  • PHB2 knockdown enhances radiosensitivity in both normoxic and hypoxic conditions.
  • PHB2 knockdown inhibits radiation-induced mitophagy and regulates PARL, PGAM5, and PINK1.
  • Mitophagy agonist CCCP reversed the effects of PHB2 knockdown.

Conclusions:

  • PHB2 knockdown reduces glioma malignancy and radioresistance by inhibiting mitophagy through the PARL-PGAM5-PINK1-Parkin pathway.
  • PHB2 represents a promising therapeutic target for improving glioma radiotherapy efficacy.
  • Targeting PHB2 could offer a novel strategy for glioma treatment.
Keywords:
PHB2gliomahypoxiamitophagyradiosensitivity

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K